The group go into the detail of chemo immune combinations and what to do next. 

The group try to get to the bottom of whether these data has made any difference in treatment and future plans. 

Andrea talks about her phase 2 trial which shows activity for Cabozantinib in urothelial cancer. 

Some thought it would never come - the final podcast of the World Tour from Boston.

Tom, Brian and Chris Sweeney discuss the challenges of development of biomarkers for immune therapy in bladder cancer. 

Tom, David and Brian discuss biomarkers in renal cancer in the era of immune therapy.

Jan Oldenburg from Norway discusses treatment choices for stage 1 testis cancer, the dilemma of high dose therapy for relapse and long term toxicity of chemotherapy. 

Axel Bex talks about small renal masses, robotic vs partial nephrectomy and surgery in metastatic disease. 

The World Tour stays in Germany to discuss the first line renal cancer (clear cell and non-clear cell) and clinical trials with Oliver Grimm.